External validation of the SORG 90-day and 1-year machine learning algorithms for survival in spinal metastatic disease.

External validation Machine learning Neurosurgery Ninety-day One year Orthopedic surgery Prediction Prognosis Spine metastasis Spine surgery Survival

Journal

The spine journal : official journal of the North American Spine Society
ISSN: 1878-1632
Titre abrégé: Spine J
Pays: United States
ID NLM: 101130732

Informations de publication

Date de publication:
01 2020
Historique:
received: 08 04 2019
revised: 03 09 2019
accepted: 04 09 2019
pubmed: 11 9 2019
medline: 12 9 2020
entrez: 11 9 2019
Statut: ppublish

Résumé

Preoperative survival estimation in spinal metastatic disease helps determine the appropriateness of invasive management. The SORG ML 90-day and 1-year machine learning algorithms for survival in spinal metastatic disease were previously developed in a single institutional sample but remain to be externally validated. The purpose of this study was to externally validate these algorithms in an independent population from another institution. Retrospective study at a large, tertiary care center. Patients 18 years or older who underwent surgery between 2003 and 2016. Ninety-day and 1-year mortality. Baseline characteristics of the validation cohort were compared to the developmental cohort for the SORG ML algorithms. Discrimination (c-statistic and receiver operating curve), calibration (calibration slope, intercept, calibration plot, and observed proportions by predicted risk groups), overall performance (Brier score), and decision curve analysis were used to assess the performance of the SORG ML algorithms in the validation cohort. Overall, 176 patients underwent surgery for spinal metastatic disease, of which 44 (22.7%) experienced 90-day mortality and 99 (56.2%) experienced 1-year mortality. The validation cohort differed significantly from the developmental cohort on primary tumor histology, metastatic tumor burden, previous systemic therapy, overall comorbidity burden, and preoperative laboratory characteristics. Despite these differences, the SORG ML algorithms generalized well to the validation cohort on discrimination (c-statistic 0.75-0.81 for 90-day mortality and 0.77-0.78 for 1-year mortality), calibration, Brier score, and decision curve analysis. Initial results from external validation of the SORG ML 90-day and 1-year algorithms for survival prediction in spinal metastatic disease suggest potential utility of these digital decision aids in clinical practice. Further studies are needed to validate or refute these algorithms in large patient samples from prospective, international, multi-institutional trials.

Sections du résumé

BACKGROUND CONTEXT
Preoperative survival estimation in spinal metastatic disease helps determine the appropriateness of invasive management. The SORG ML 90-day and 1-year machine learning algorithms for survival in spinal metastatic disease were previously developed in a single institutional sample but remain to be externally validated.
PURPOSE
The purpose of this study was to externally validate these algorithms in an independent population from another institution.
STUDY DESIGN/SETTING
Retrospective study at a large, tertiary care center.
PATIENT SAMPLE
Patients 18 years or older who underwent surgery between 2003 and 2016.
OUTCOME MEASURES
Ninety-day and 1-year mortality.
METHODS
Baseline characteristics of the validation cohort were compared to the developmental cohort for the SORG ML algorithms. Discrimination (c-statistic and receiver operating curve), calibration (calibration slope, intercept, calibration plot, and observed proportions by predicted risk groups), overall performance (Brier score), and decision curve analysis were used to assess the performance of the SORG ML algorithms in the validation cohort.
RESULTS
Overall, 176 patients underwent surgery for spinal metastatic disease, of which 44 (22.7%) experienced 90-day mortality and 99 (56.2%) experienced 1-year mortality. The validation cohort differed significantly from the developmental cohort on primary tumor histology, metastatic tumor burden, previous systemic therapy, overall comorbidity burden, and preoperative laboratory characteristics. Despite these differences, the SORG ML algorithms generalized well to the validation cohort on discrimination (c-statistic 0.75-0.81 for 90-day mortality and 0.77-0.78 for 1-year mortality), calibration, Brier score, and decision curve analysis.
CONCLUSION AND RELEVANCE
Initial results from external validation of the SORG ML 90-day and 1-year algorithms for survival prediction in spinal metastatic disease suggest potential utility of these digital decision aids in clinical practice. Further studies are needed to validate or refute these algorithms in large patient samples from prospective, international, multi-institutional trials.

Identifiants

pubmed: 31505303
pii: S1529-9430(19)30967-2
doi: 10.1016/j.spinee.2019.09.003
pii:
doi:

Types de publication

Journal Article Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

14-21

Informations de copyright

Copyright © 2019. Published by Elsevier Inc.

Auteurs

Aditya V Karhade (AV)

Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Ali K Ahmed (AK)

Department of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Zach Pennington (Z)

Department of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Alejandro Chara (A)

Department of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Andrew Schilling (A)

Department of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Quirina C B S Thio (QCBS)

Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Paul T Ogink (PT)

Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Daniel M Sciubba (DM)

Department of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Joseph H Schwab (JH)

Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: jhschwab@mgh.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH